AlSaadoun Aljawhara R, AlSaadoun Tariq R, Al Ghumlas Abdullah K
Family and Community Medicine, King Fahad University Hospital/Imam Abdulrahman Bin Faisal University, Dammam, SAU.
Cureus. 2022 Jan 25;14(1):e21616. doi: 10.7759/cureus.21616. eCollection 2022 Jan.
Liraglutide, a long-acting cardioprotective glucagon-like peptide (GLP)-1 analog, is effective for medical weight loss and glycemic control in type 2 diabetes. It is generally well tolerated with mild side effects. There are few reports on complications from Liraglutide overdose. The aim of this paper is to report the case of a 25-year-old healthy female who presented with acute pancreatitis secondary to Liraglutide overdose and to review the current literature on Liraglutide used for obesity management. The current literature examining the association between acute pancreatitis and Liraglutide use, and Liraglutide overdose are inconclusive. Further research is recommended.
利拉鲁肽是一种长效具有心脏保护作用的胰高血糖素样肽（GLP）-1类似物，对2型糖尿病患者的医学减重和血糖控制有效。它通常耐受性良好，副作用轻微。关于利拉鲁肽过量导致并发症的报道很少。本文旨在报告一例25岁健康女性因利拉鲁肽过量继发急性胰腺炎的病例，并综述目前关于利拉鲁肽用于肥胖管理的文献。目前研究急性胰腺炎与利拉鲁肽使用及利拉鲁肽过量之间关联的文献尚无定论。建议进一步开展研究。
